First Patient Dosed in GE HealthCare’s Phase II/III LUMINA Clinical Trial

First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial

GE HealthCare has dosed the first patient in its Phase II/III LUMINA clinical trial for the investigational manganese-based MRI contrast agent, mangaciclanol.The post First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial appeared first on Medical Device Network.

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designation The program more... The post GE HealthCare Announces…

GE HealthCare: First Patient Dosed in Trial for Manganese-based MRI Contrast Agent

Currently under FDA Fast Track Designation, Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents.